Switching HIV Regimens

Switching to emtricitabine/tenofovir alafenamide (Biktarvy, Gilead), a once-daily single tablet regimen, in virologically suppressed adults with HIV was found to be statistically non-inferior to a regimen containing abacavir, dolutegravir and lamivudine with a lower incidence of mild or moderate study drug-related adverse events and no treatment-emergent resistance. The data were presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in